Andrew Dawson was Resigned as Senior Vice President and Head of Human Resources at Enzyvant

Date of management change: February 03, 2019 

What Happened?

Cambridge, MA-based Enzyvant Resigned Andrew Dawson as Senior Vice President and Head of Human Resources

 

About the Company

Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.

 

About the Person

Andrew Dawson is Chief Human Resources Officer at Cedilla Therapeutics. Previously, Andrew held various senior HR leadership roles in the industry.

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Cahoon Scott, Shelef Keren, Curran John, Nguyen Dat, Hutchinson Pamela, Pragano Cathie, Trubshaw April, Spieler Pamela, McQueen Nina, Dorsey Zeke, Ricaurte Michael

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.